Brivanib fails to match sorafenib for liver cancer, but tivantinib looks promising
Nucleoside analogues reduce hepatitis B liver cancer risk
Tenofovir safe and effective for long-term hepatitis B treatment with little bone loss
New cohort shows the impact of hepatitis B and hepatitis C on the 'baby boom' generation
Dramatic increase in incidence of liver cancer in HIV-positive people with viral hepatitis
Switching to tenofovir suppresses hepatitis B in HIV/HBV co-infected people
Hepatitis B vaccine is effective for up to 15 years
Hepatitis B is a major health issue for migrants in the US
Brivanib did not improve overall liver cancer survival, but did show anti-tumour activity
![Josep Llovet, University of Barcelona [Photo by Liz Highleyman, hivandhepatitis.com]](https://ik.imagekit.io/ftwmbwg7i/tr:w-640,h-480,q-80,fo-auto,f-auto/https%3A%2F%2Fcdn.craft.cloud%2F019ecfe4-fa59-7378-875f-6ad629d65a81%2Fassets%2F2012-04%2Fbrivanib-did-not-improve-overall-liver-cancer-survival-but-did-show-anti-tumour-activity.jpg?ik-s=72da0bc390c58f9e219054c2b59b14a731faf359&ik-t=7552444800)